Table II.
Patient demographics and clinical characteristics (n=107) based on outcome.
| Clinicopathological characteristics | Non-Survivors (n=40) | Survivors (n=67) | P-value | χ2 value | Total (n=107) |
|---|---|---|---|---|---|
| Sex, n (% male) | 24 (67.5) | 41 (61.2) | 0.903 | 0.015 | 65 (60.7) |
| Age, years | 70.47±6.214 | 69.33±5.634 | 0.329 | 0.980 | 69.76±4.773 |
| Comorbidities, n (%) | |||||
| Hypertension | 22 (55) | 36 (53.7) | 0.899 | 0.016 | 58 (54.2) |
| Diabetes | 12 (30) | 17 (25.4) | 0.602 | 0.217 | 29 (27.1) |
| Immune diseases | 7 (17.5) | 6 (8.95) | 0.191 | 1.713 | 13 (12.1) |
| Cardiovascular disease | 26 (65) | 38 (56.7) | 0.398 | 0.715 | 64 (59.8) |
| Liver disease | 3 (7.5) | 2 (2.99) | 0.360 | 0.357 | 5 (4.67) |
| COPD | 8 (20) | 11 (16.4) | 0.639 | 0.220 | 19 (17.7) |
| Noradrenaline use, n (%) | 37 (92.5) | 18 (26.9) | ≤0.001a | 43.193 | 55 (51.4) |
| Mechanical ventilation, n (%) | 33 (82.5) | 35 (52.2) | 0.002a | 9.902 | 68 (63.5) |
| SOFA | 9.15±3.051 | 5.328±3.012 | ≤0.001a | 6.319 | 6.757±3.10 |
| APACHE II | 21.97±6.282 | 14.70±5.359 | ≤0.001a | 6.364 | 17.42±2.28 |
| AKI | 16 (40) | 13 (19.4) | 0.020a | 5.378 | 29 (27.1) |
| KDIGO, n (%): | |||||
| I | 2 (5) | 1 (1.49) | 0.554 | 0.131 | 32.80 |
| II | 5 (12.5) | 4 (5.97) | 0.290 | 0.668 | 9 (8.41) |
| III | 10 (25) | 7 (10.4) | 0.046a | 3.969 | 17 (15.9) |
| Need for dialysis, n (%) | 13 (32.5) | 6 (8.95) | 0.002a | 9.508 | 19 (17.8) |
AKI, acute kidney injury; COPD, chronic obstructive pulmonary disease; APACHE, Acute Physiology And Chronic Health Evaluation; SOFA, sequential organ failure assessment.
a
P>0.05, no significant difference. Values are expressed as the mean and standard deviation or the median and interquartile range.